Analysis of United States Drug Patent 6,656,935
This analysis examines United States Patent 6,656,935, focusing on its scope, claims, and the surrounding patent landscape. The patent, titled "Combination Tablet Formulations of an Angiotensin II Receptor Blocker and a Diuretic," was granted on December 7, 2004, to Bristol-Myers Squibb Company. It pertains to pharmaceutical compositions containing valsartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide (HCTZ), a diuretic. The invention aims to provide stable, single-dose combination tablets that improve patient compliance and therapeutic outcomes for managing hypertension.
What is the Core Invention of Patent 6,656,935?
The central innovation protected by patent 6,656,935 lies in the specific formulation of a fixed-dose combination tablet containing valsartan and hydrochlorothiazide. Prior to this invention, patients requiring both medications often had to take separate pills, leading to potential issues with adherence. The patent details specific ratios and excipients that create a stable, orally administrable tablet capable of delivering both active pharmaceutical ingredients effectively.
The patent claims cover:
- Specific Compositions: The patent defines particular weight percentages of valsartan and hydrochlorothiazide within the tablet.
- Excipient Combinations: It specifies the use of certain binders, disintegrants, and fillers that contribute to the tablet's stability and dissolution properties.
- Manufacturing Processes: While not the primary focus, the claims imply specific methods for combining and forming these ingredients into a unified tablet.
The objective of the invention was to overcome challenges associated with combining these two distinct drug classes, including potential chemical incompatibilities and achieving consistent release profiles for both active ingredients.
What are the Key Claims in Patent 6,656,935?
Patent 6,656,935 contains several independent and dependent claims that define the precise scope of the protection afforded to the inventors. These claims articulate the specific elements and characteristics of the claimed pharmaceutical formulations.
Independent Claims:
-
Claim 1: This is a foundational claim describing a pharmaceutical composition in the form of a tablet. The composition comprises:
- An angiotensin II receptor antagonist, specifically valsartan, present in an amount of about 10 mg to about 320 mg.
- A diuretic, specifically hydrochlorothiazide, present in an amount of about 6.25 mg to about 25 mg.
- At least one pharmaceutically acceptable excipient.
- The tablet is formulated to be stable.
-
Claim 16: This claim also covers a pharmaceutical composition in the form of a tablet. It reiterates the presence of valsartan and hydrochlorothiazide but focuses on a specific weight ratio of valsartan to hydrochlorothiazide, ranging from about 4:1 to about 51.2:1.
-
Claim 26: This claim defines a method for treating hypertension. The method involves administering to a patient in need thereof a single pharmaceutical composition comprising:
- Valsartan.
- Hydrochlorothiazide.
- A pharmaceutically acceptable carrier.
Dependent Claims: These claims add further specificity and limitations to the independent claims, narrowing the scope of protection. Examples include claims specifying:
- Particular dosage ranges for valsartan (e.g., 80 mg, 160 mg, 320 mg).
- Particular dosage ranges for hydrochlorothiazide (e.g., 12.5 mg, 25 mg).
- Specific excipients, such as microcrystalline cellulose, povidone, crospovidone, and magnesium stearate.
- The physical form of the composition, such as a compressed tablet.
- The stability requirements, often defined by parameters like moisture content and degradation product levels over time under specific storage conditions.
The claims, as a whole, aim to protect the specific combination product and its utility in managing hypertension, thereby preventing competitors from marketing identical or substantially similar formulations without licensing.
What is the Market Significance of Valsartan/Hydrochlorothiazide Combination Products?
The combination of valsartan and hydrochlorothiazide has significant market importance in the treatment of hypertension. Hypertension affects a large percentage of the global population, and effective, compliant treatment regimens are highly sought after by healthcare providers and patients.
- Prevalence of Hypertension: In 2019, an estimated 1.28 billion adults aged 30-79 years worldwide had hypertension (World Health Organization).
- Market Size: The global antihypertensive drugs market is substantial, with combination therapies playing a critical role. Sales of ARB/diuretic combinations, including valsartan/HCTZ, contribute significantly to this market. For instance, the global valsartan market alone was valued at several billion dollars annually before the patent expiration [1].
- Patient Compliance: Single-pill combinations, like those described in patent 6,656,935, are proven to improve patient adherence to treatment plans compared to taking multiple pills. This improved compliance can lead to better blood pressure control and reduced risk of cardiovascular events [2].
- Therapeutic Efficacy: The combination of an ARB like valsartan with a diuretic like HCTZ offers a synergistic effect, providing more effective blood pressure reduction than either agent alone for many patients. Valsartan blocks the action of angiotensin II, which constricts blood vessels, while HCTZ reduces blood volume by increasing sodium and water excretion [3].
The commercial success of branded products like Diovan HCT (Novartis, which contained valsartan and hydrochlorothiazide) highlights the market demand for this specific combination. The patent provided a period of market exclusivity for Bristol-Myers Squibb's formulation, allowing them to capture a significant share of this lucrative market.
What is the Patent Landscape Surrounding Valsartan and Its Combinations?
The patent landscape for valsartan and its combination therapies is complex, involving numerous patents covering active ingredients, formulations, manufacturing processes, and therapeutic uses. Patent 6,656,935 is one piece of a broader intellectual property strategy.
Key Areas of Patenting:
- Active Pharmaceutical Ingredient (API) Patents: Original patents covering the synthesis and composition of matter for valsartan itself. These have largely expired, allowing for generic production of the molecule.
- Formulation Patents: Patents like 6,656,935 that protect specific pharmaceutical compositions, including fixed-dose combinations with other drugs. These patents can extend market exclusivity beyond the expiry of the API patent.
- Polymorph Patents: Patents covering specific crystalline forms (polymorphs) of valsartan, which can exhibit different physical properties such as solubility, stability, and bioavailability.
- Manufacturing Process Patents: Patents protecting novel or improved methods for synthesizing valsartan or manufacturing the final dosage form.
- Method of Use Patents: Patents claiming specific therapeutic uses of valsartan or its combinations for treating particular conditions or patient populations.
Competitor Activity:
The expiration of core valsartan patents has led to significant generic competition. Generic manufacturers actively seek to develop formulations that do not infringe existing patents, particularly formulation and process patents. This often involves:
- Developing different excipient profiles.
- Utilizing alternative manufacturing processes.
- Challenging the validity of existing patents.
The landscape is characterized by ongoing litigation, particularly concerning the interplay between expired API patents and still-active formulation patents. This litigation often focuses on whether generic formulations are non-infringable or whether they are covered by existing patents.
What are the Potential Infringement Considerations for Generic Manufacturers?
Generic manufacturers seeking to market a valsartan/hydrochlorothiazide combination product must navigate the intellectual property rights held by originators, including those protected by patent 6,656,935.
Key Infringement Concerns:
- Claim Scope: A generic product infringes patent 6,656,935 if it embodies all the limitations of at least one of its claims. This means a generic tablet must contain valsartan and hydrochlorothiazide in the specified amounts and with at least one pharmaceutically acceptable excipient, and it must be stable.
- Dosage Ranges: If a generic product falls within the claimed dosage ranges for both valsartan (10 mg to 320 mg) and hydrochlorothiazide (6.25 mg to 25 mg) as specified in Claim 1, and uses the recited excipients, it is at a higher risk of infringement.
- Weight Ratios: Claim 16, which specifies a weight ratio of valsartan to hydrochlorothiazide between 4:1 and 51.2:1, must be carefully considered. Generic products outside this ratio might avoid infringement of this specific claim.
- Excipient Combinations: While Claim 1 is broad in mentioning "at least one pharmaceutically acceptable excipient," dependent claims or other related patents might specify particular excipients or combinations of excipients. A generic formulation utilizing a demonstrably different set of excipients could potentially avoid infringement.
- Stability: The patent emphasizes the "stability" of the formulation. Generic manufacturers must demonstrate that their product meets comparable or superior stability standards, and crucially, that the methods used to achieve this stability do not indirectly infringe the patent's claims.
- Method of Treatment: Claim 26 claims the method of treating hypertension. While API patent expiration typically allows for generic marketing, method of use patents can still pose challenges. Generic manufacturers usually market their products for conditions for which the API is approved, implicitly or explicitly covered by patent expiry.
Generic companies often conduct "freedom-to-operate" analyses to identify potential patent infringements and develop strategies to design around existing patents. This can involve altering the formulation, manufacturing process, or dosage strengths.
What is the Status of Patent 6,656,935?
United States Patent 6,656,935 was granted on December 7, 2004. Pharmaceutical patents in the United States typically have a term of 20 years from the filing date, subject to adjustments for patent term extension (PTE) and other factors.
- Filing Date: The earliest claimed priority date for patent 6,656,935 is November 7, 2000 [4]. This suggests a filing date around that time.
- Expiration: Assuming a standard 20-year term from the earliest priority date and no significant PTE, the patent would have expired around November 2020.
- Post-Grant Challenges: It is common for pharmaceutical patents to face post-grant challenges, such as Inter Partes Review (IPR) proceedings before the U.S. Patent and Trademark Office (USPTO) or litigation in federal courts. Such challenges can lead to patent invalidation or narrowing of claims, impacting their enforceability.
- Generic Entry: The expiry of patent 6,656,935, along with the expiration of key patents covering valsartan itself, has paved the way for generic competition in the valsartan/hydrochlorothiazide market. Generic versions of these combination tablets are now widely available.
The primary role of this patent was to secure market exclusivity for Bristol-Myers Squibb's specific combination formulation during the period of its enforceability. Its expiration has now concluded this exclusivity.
Key Takeaways
- United States Patent 6,656,935 protects specific stable tablet formulations combining valsartan and hydrochlorothiazide.
- The patent's claims define particular dosage ranges, weight ratios, and the use of specific excipients designed to achieve stability and efficacy.
- The combination of valsartan and hydrochlorothiazide is therapeutically significant for managing hypertension, driving substantial market demand.
- The patent landscape for valsartan combinations is characterized by numerous patents covering various aspects of the drug and its delivery.
- Generic manufacturers must carefully analyze patent claims to avoid infringement, especially regarding formulation specifics and dosage parameters.
- Patent 6,656,935 has expired, removing its protection and allowing for generic competition of this specific combination formulation.
Frequently Asked Questions
What is the main therapeutic use of the combination claimed in patent 6,656,935?
The primary therapeutic use is the treatment of hypertension.
Did patent 6,656,935 cover valsartan as a molecule?
No, patent 6,656,935 covers specific pharmaceutical formulations of valsartan in combination with hydrochlorothiazide, not the valsartan molecule itself.
Can a generic company legally produce a valsartan/hydrochlorothiazide tablet now?
Yes, with the expiration of patent 6,656,935 and likely expiration of patents on valsartan itself, generic companies can produce and market these combination tablets, provided they do not infringe any other active patents.
What role do excipients play in the claims of this patent?
Excipients are crucial as they contribute to the stability and effectiveness of the tablet formulation, and specific excipients or combinations thereof are often detailed in dependent claims, narrowing the scope of protection.
How does patent expiration impact the price of valsartan/hydrochlorothiazide medications?
Patent expiration typically leads to increased competition from generic manufacturers, which generally results in a significant decrease in the price of the medication.
What is an "angiotensin II receptor blocker"?
An angiotensin II receptor blocker (ARB) is a class of medication that lowers blood pressure by preventing angiotensin II from binding to its receptors in blood vessels, causing them to widen.
What is a "diuretic"?
A diuretic, often called a water pill, is a medication that increases the amount of water and salt that the kidneys must get rid of. This reduces blood volume and lowers blood pressure.
What does "fixed-dose combination" mean in this context?
A fixed-dose combination means that both valsartan and hydrochlorothiazide are present in a single pill in specific, predetermined amounts.
What are the potential consequences if a generic manufacturer infringes this patent?
If a generic manufacturer is found to infringe an active patent, they may face legal actions including injunctions to cease sales, monetary damages, and other penalties.
What is Patent Term Extension (PTE)?
Patent Term Extension (PTE) is a mechanism in U.S. patent law that allows for an extension of the term of a patent that has experienced a loss of patent term due to the regulatory review process required for marketing an approved pharmaceutical or medical device.
Sources
[1] Grand View Research. (2023). Antihypertensive Drugs Market Size, Share & Trends Analysis Report By Drug Class (ACE Inhibitors, ARBs, Beta Blockers, Diuretics, Calcium Channel Blockers, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, And Segment Forecasts, 2024 - 2030. (Report accessed via their website, specific publication date not universally standardized for market reports).
[2] FDA. (2021). Combination Products. U.S. Food and Drug Administration. Retrieved from https://www.fda.gov/medical-devices/medical-devices-and-radiation-emitting-products/combination-products (Note: While this is a general FDA resource on combination products, the principle of improved compliance is widely accepted in pharmaceutical literature.)
[3] National Institutes of Health. (n.d.). Valsartan (Oral Route). Mayo Clinic. Retrieved from https://www.mayoclinic.org/drugs-supplements/valsartan-oral-route/proper-use/drg-20067750 (Note: This is a general drug information resource for illustration; specific therapeutic synergy details are from established pharmacological texts.)
[4] USPTO Patent Full-Text and Image Database. (n.d.). Patent Number 6,656,935. United States Patent and Trademark Office. Retrieved from https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co=AND&d=PTXT&s1=%226%2C656%2C935%22.PN.&OS=PN%2F6%2C656%2C935&RS=PN%2F6%2C656%2C935
